#ronaldo #cristianoronaldo #cr7 #goat #legend #icon #Portugal #sports #goal June 11, 2024 Portugal played a friendly vs Ireland, and guess who scored? ... https://www.youtube.com/watch?v=abCVJDMG5yQ

Hot Stocks Balling in Bali: $VERB, $GERN, $BTTX, $JTAI, $CDLX - RICH TV - March 15, 2024 - #BTC #HOTSTOCKS #HOT #STOCKS #dowjones #meltup #bitcoin #crypto #commodities #gold #silver #oil #stocks #richtv #richtvlive #richtv #buy #education #investing #stocks #chat #analysis #stockmarket #rich #HOTSTOCKS #inflation #cpi #richtvlivepodcast #NASDAQ #ETHEREUM #ETH JOIN RICH TV LIVE TRADING CLUB HERE - http://www.richtv.io https://www.youtube.com/c/RICHTVLIVE Social Media Links - https://linktr.ee/richtvlive Ledger - Home of the first and only certified Hardware wallets https://bit.ly/richtv-Ledger Popular Uploads - https://goo.gl/tbvXGg Most Recent Upload - https://goo.gl/unKXBy YouTube Channel Page - https://goo.gl/yUdG7w Disclaimer RICH TV LIVE INC. company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RICH TV LIVE reports company profiles or other investor relations materials and presentations are subject to change. RICH TV LIVE and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. Investing is inherently risky. RICH TV LIVE is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov/Canadian CSA https://www.securities-administrators.... ... https://www.youtube.com/watch?v=zhHksUVqdo4

#railaybeach #krabi #aonang #Thailand #travel #beach #water #ocean #people April 28, 2024 Railay Beach, Ao Nang, Krabi, Thailand ... https://www.youtube.com/watch?v=w04ShEH--UM

PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) * FDA APPROVAL - RICH TV LIVE - May 17, 2021 - PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Investigational New Drug (“IND”) application to proceed with a Phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease (“LID-PD”). PharmaTher expects to begin enrolling patients in the Phase 2 clinical trial in Q3-2021. Assuming the Phase 2 clinical trial is positive, the Company will request a meeting with the FDA to discuss its plan and obtain an agreement to move to a Phase 3 clinical study under the 505(b)(2) regulatory pathway next year. Fabio Chianelli, Chief Executive Officer of PharmaTher, said, “The FDA’s acceptance of our IND application for ketamine to treat Parkinson’s disease is a significant milestone for us. The FDA IND is our first of many we will aim to obtain, and we are one of the few psychedelics-focused biotech companies that have an IND approved by the FDA for a recognized psychedelic drug. The IND paves the way for us to expeditiously evaluate ketamine and other psychedelics via the FDA regulatory pathway in various mental illness, neurological and pain disorders. We are committed to building a rich product pipeline of novel uses, formulations and delivery methods of psychedelics, and with our FDA IND in place, we now have the foundation in making PharmaTher a global leader in psychedelic-based therapeutics.” Parkinson’s disease is a debilitating disorder that affects over 1 million people in the U.S. and more than 7 million people worldwide. There is currently no cure for Parkinson’s disease, although some drug combinations are used to treat the disease symptoms. The global Parkinson’s disease market is expected to grow from USD $5 billion in 2019 to USD $7.5 billion by the end of 2025 [360iResearch 2020] and it is estimated that the potential market opportunity for LID-PD to be over USD $3 billion in the U.S. alone. About the Phase 2 Clinical Trial The clinical trial is titled “A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo-Controlled Trial of Sub-Anesthetic Ketamine to Treat Levodopa-Induced Dyskinesia in Subjects with Parkinson’s Disease.” It is anticipated that up to eight clinical sites in the U.S. will randomize a total of up to 36 subjects to the investigational product (ketamine) or active control (midazolam). The primary end-point of the study is the change in the Unified Dyskinesia Rating Scale (“UDysRS”) ... https://www.youtube.com/watch?v=64GPFjZtR38